Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of GSK217744 in Infants
NCT01248884Phase 2Completed
- Sponsor
- GSK
- Start
- Dec 2010
- Primary completion
- Jan 2012
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised trial of Infanrix Hexa in diphtheria, Tetanus, pertussis and 3 more (3 arms), sponsored by GSK. Primary endpoints: Number of Seroprotected Subjects for Anti-diphtheria (Anti-D) Antibodies at Month 3, Number of Seroprotected Subjects for Anti-tetanus (Anti-T) Antibodies at Month 3 and 5 more. Started Dec 2010; status: completed.
02
Drugs
Infanrix Hexa
03
Conditions
diphtheriaTetanuspertussishepatitis B (HBV)poliomyelitis
Beyond the preview
Go deeper on NCT01248884.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01248884.